FY2025 EPS Estimates for Humacyte Raised by HC Wainwright

Humacyte, Inc. (NASDAQ:HUMA) – Equities researchers at HC Wainwright upped their FY2025 earnings estimates for Humacyte in a report issued on Thursday, November 13th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of ($0.63) for the year, up from their prior forecast of ($0.75). HC Wainwright currently has a “Buy” rating and a $3.00 price target on the stock. The consensus estimate for Humacyte’s current full-year earnings is ($1.27) per share. HC Wainwright also issued estimates for Humacyte’s Q4 2025 earnings at ($0.13) EPS, FY2026 earnings at ($0.50) EPS, FY2027 earnings at ($0.32) EPS, FY2028 earnings at $0.08 EPS and FY2029 earnings at $0.31 EPS.

Humacyte (NASDAQ:HUMA) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.03. The firm had revenue of $0.75 million for the quarter, compared to the consensus estimate of $0.92 million.

Several other brokerages have also recently commented on HUMA. Barclays started coverage on shares of Humacyte in a research report on Wednesday, August 27th. They issued an “overweight” rating and a $3.50 price target on the stock. Benchmark dropped their target price on shares of Humacyte from $14.00 to $11.00 and set a “buy” rating on the stock in a report on Thursday, November 13th. BTIG Research cut their target price on shares of Humacyte from $7.00 to $6.00 and set a “buy” rating for the company in a research note on Monday, October 13th. Weiss Ratings restated a “sell (e+)” rating on shares of Humacyte in a research report on Wednesday, October 8th. Finally, Wall Street Zen cut Humacyte from a “hold” rating to a “sell” rating in a report on Sunday, August 17th. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Humacyte presently has an average rating of “Moderate Buy” and a consensus target price of $8.29.

Humacyte Trading Down 8.1%

Shares of Humacyte stock opened at $1.13 on Monday. The business has a fifty day simple moving average of $1.62 and a 200-day simple moving average of $1.94. Humacyte has a fifty-two week low of $1.12 and a fifty-two week high of $6.77. The firm has a market cap of $178.96 million, a price-to-earnings ratio of -4.91 and a beta of 1.88. The company has a quick ratio of 0.90, a current ratio of 1.62 and a debt-to-equity ratio of 2.97.

Institutional Trading of Humacyte

Several hedge funds and other institutional investors have recently modified their holdings of the business. Imprint Wealth LLC purchased a new position in shares of Humacyte during the third quarter valued at $33,000. Raymond James Financial Inc. boosted its position in Humacyte by 549.2% during the 3rd quarter. Raymond James Financial Inc. now owns 72,128 shares of the company’s stock worth $126,000 after acquiring an additional 61,017 shares during the period. Equitable Holdings Inc. purchased a new position in Humacyte during the 3rd quarter valued at about $29,000. BNP Paribas Financial Markets grew its stake in Humacyte by 87.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 91,740 shares of the company’s stock valued at $160,000 after acquiring an additional 42,701 shares in the last quarter. Finally, Private Advisor Group LLC increased its holdings in shares of Humacyte by 2.6% in the 3rd quarter. Private Advisor Group LLC now owns 1,029,080 shares of the company’s stock valued at $1,791,000 after purchasing an additional 26,400 shares during the period. Institutional investors and hedge funds own 44.71% of the company’s stock.

Insider Activity at Humacyte

In other news, Director Brady W. Dougan sold 591,685 shares of the business’s stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $1.58, for a total transaction of $934,862.30. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Laura E. Niklason sold 591,685 shares of the company’s stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $1.58, for a total transaction of $934,862.30. The SEC filing for this sale provides additional information. Company insiders own 5.10% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.